NCT00158028 - Risperidone in the Treatment of Psychotic-like and Deficit Symptoms of Schizotypal Personality Disorder | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 1995

Primary Completion Date

December 31, 2001

Study Completion Date

December 31, 2001

Conditions

Schizotypal Personality Disorder

Interventions

DRUG

Risperidone

The dosage of risperidone was titrated upward in a stepwise design, beginning with 0.25 mg/d for the first week, 0.5 mg/d for weeks 2 and 3, 1.0 mg/d for weeks 4 and 5, 1.5 mg/d for weeks 6 and 7, and 2.0 mg/d for the remaining weeks.

DRUG

Placebo

placebo match in identical tablets

Trial Locations (1)

10029

Bronx VA, The Bronx